FindTrial
Sign In

Compassionate Use of REGN-COV2 for the Treatment of COVID-19

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04617535
Enrollment
Unknown
Registered
2020-11-05
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Keywords

Post-exposure

Brief summary

Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

Detailed description

Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.

Interventions

DRUGREGN10933+REGN10987 combination therapy

Administered intravenously (IV) single dose

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026